Cost-effectiveness of genetic screening for maturity onset diebetes of the young (Mody)

@inproceedings{Carter2017CosteffectivenessOG,
  title={Cost-effectiveness of genetic screening for maturity onset diebetes of the young (Mody)},
  author={Hannah Elizabeth Carter and Samantha A Hollingworth and Emma L Duncan and Brown and Eric Davis and Nicholas Graves and Staci R. Johnson},
  year={2017}
}
OBJECTIVES Maturity onset diabetes of the young (MODY) is a genetic form of diabetes for which 13 genes are known to be responsible. Many subtypes of MODY can be treated with oral medication instead of insulin injections, which results in improved metabolic control, quality of life and cost savings. Massively parallel sequencing (MPS) enables the simultaneous sequencing of all 13 genes for a fraction of the cost of traditional Sanger sequencing. We conducted a cost utility analysis of… CONTINUE READING

Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

Topics from this paper.